Skip to main content
SpringerLink
Log in

A Profile of Adverse Drug Reactions of Atazanavir- and Lopinavir-Based Antiretroviral Regimens in Namibia

  • Research Letter
  • Published:
Drug Safety Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Onoya D, Hirasen K, van den Berg L, Mot J, Long LC, Fox MP. Adverse drug reactions among patients initiating second-line antiretroviral therapy in South Africa. Drug Saf. 2018;41(12):1343–53.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Zash R, Makhema J, Shapiro RL. Neural-tube defects with Dolutegravir treatment from the time of conception. N Engl J Med. 2018;379:979–81.

    Article  PubMed Central  PubMed  Google Scholar 

  3. MoHSS Summary sheet: preliminary findings—Namibia population-based HIV impact assessment NAMPHIA 2017. 2018.

  4. Ministry of Health and Social Services. National Guidelines for Antiretroviral Therapy. Fifth edition. 2016. https://aidsfree.usaid.gov/sites/default/files/na_national_guidelines_art.pdf. Accessed 7 May 2019.

  5. Pierce CE, de Vries ST, Bodin-Parssinen S, Hamark L, Tregunno P, Lewis DJ, et al. Recommendations on the Use of mobile applications for the collection and communication of pharmaceutical product safety information: lessons from IMI WEB-RADR. Drug Saf. 2019;42(4):477–89.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Namibia Medicines Regulatory Council, Windhoek, Namibia

    Babafunso Aderemi Adenuga

  2. School of Pharmacy, University of Namibia, Windhoek, Namibia

    Timothy William Rennie

Authors
  1. Babafunso Aderemi Adenuga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timothy William Rennie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timothy William Rennie.

Ethics declarations

Funding

No sources of funding were used to assist in the preparation of this letter.

Conflicts of interest

Babafunso Aderemi Adenuga and Timothy Rennie have no conflicts of interest that are directly relevant to the content of this letter.

Ethics

The Research Ethics Boards of the MoHSS (reference no. 17/3/3) and Ethics Committee of the University of Namibia (reference no. SOPHA/209/2017) approved the study. Secondary data were used in this study and the need for written informed consent was waived by the Research Ethics Committee.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adenuga, B.A., Rennie, T.W. A Profile of Adverse Drug Reactions of Atazanavir- and Lopinavir-Based Antiretroviral Regimens in Namibia. Drug Saf 42, 915–917 (2019). https://doi.org/10.1007/s40264-019-00832-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-019-00832-3

Search

Navigation